SubHero Banner

Enhertu® (fam-trastuzumab deruxtecan-nxki) – New indication

August 5, 2022 - The FDA announced the approval of Astra Zeneca and Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki), for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+/ in situ hybridization [ISH]-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

Download PDF